# MSC for Treatment of cGVHD After Allo-HSCT

> **NCT04692376** · PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 152 (estimated)

## Conditions studied

- Chronic Graft-versus-host Disease

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cells
- **DRUG:** Glucocorticoids
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT04692376
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-10
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2020-12-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692376, "MSC for Treatment of cGVHD After Allo-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04692376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*